PDF(Pubmed)
Abstract：
UNASSIGNED: Immunoglobulin A nephropathy (IgAN) and IgA vasculitis with nephritis (IgAV-N) are considered related diseases and share some similar clinicopathologic phenotypes. Elevated circulating galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes and mucosal immunity were associated with the pathogenesis of IgAN and IgAV-N. Recently, studies have identified that the zonulin level, as a modulator of intestinal permeability, is significantly elevated in several inflammatory and autoimmune-related diseases. However, whether zonulin also plays a role in IgAN and IgAV-N is not clear.
UNASSIGNED: A total of 73 IgAV-N patients, 68 IgAN patients and 54 healthy controls were assessed for circulating zonulin and Gd-IgA1 levels by enzyme-linked immunosorbent assay. The diagnostic efficiency of the combination of zonulin with Gd-IgA1 was evaluated by the area under the receiver operating characteristic curve (AUC) and integrated discrimination improvement (IDI) analysis.
UNASSIGNED: Compared with healthy controls, we found that both IgAV-N and IgAN patients had elevated zonulin and Gd-IgA1 levels (P < .001). Additionally, patients with IgAV-N presented with even higher circulating zonulin levels than patients with IgAN (P = .020). The addition of zonulin to Gd-IgA1 showed better predictive performance than Gd-IgA1 alone in the diagnosis of both IgAN and IgAV-N, as illustrated by a significantly increased AUC (IgAN: 0.805 versus 0.708, P = .0021; IgAV-N: 0.886 versus 0.673, P < .001) and significant IDI (IgAN: IDI 0.136, P < .001; IgAV-N: IDI 0.281, P < .001).
UNASSIGNED: Elevated circulating zonulin levels were detected in both patients with IgAV-N and those with IgAN. Combined detection of circulating zonulin and Gd-IgA1 is recommended as a noninvasive diagnostic biomarker for IgAV-N and IgAN.
UNASSIGNED: A total of 73 IgAV-N patients, 68 IgAN patients and 54 healthy controls were assessed for circulating zonulin and Gd-IgA1 levels by enzyme-linked immunosorbent assay. The diagnostic efficiency of the combination of zonulin with Gd-IgA1 was evaluated by the area under the receiver operating characteristic curve (AUC) and integrated discrimination improvement (IDI) analysis.
UNASSIGNED: Compared with healthy controls, we found that both IgAV-N and IgAN patients had elevated zonulin and Gd-IgA1 levels (P < .001). Additionally, patients with IgAV-N presented with even higher circulating zonulin levels than patients with IgAN (P = .020). The addition of zonulin to Gd-IgA1 showed better predictive performance than Gd-IgA1 alone in the diagnosis of both IgAN and IgAV-N, as illustrated by a significantly increased AUC (IgAN: 0.805 versus 0.708, P = .0021; IgAV-N: 0.886 versus 0.673, P < .001) and significant IDI (IgAN: IDI 0.136, P < .001; IgAV-N: IDI 0.281, P < .001).
UNASSIGNED: Elevated circulating zonulin levels were detected in both patients with IgAV-N and those with IgAN. Combined detection of circulating zonulin and Gd-IgA1 is recommended as a noninvasive diagnostic biomarker for IgAV-N and IgAN.
摘要：
未经证实：免疫球蛋白A肾病（IgAN）和IgA血管炎伴肾炎（IgAV-N）被认为是相关疾病，并具有一些相似的临床病理表型。循环中含有半乳糖缺陷型IgA1（Gd-IgA1）的免疫复合物和粘膜免疫与IgAN和IgAV-N的发病机制有关。最近,研究表明，zonulin水平，作为肠道通透性的调节剂，在几种炎症和自身免疫相关疾病中显著升高。然而,连带蛋白是否在IgAN和IgAV-N中也起作用尚不清楚。
未经证实：总共73例IgAV-N患者，通过酶联免疫吸附试验评估了68例IgAN患者和54例健康对照的循环zonulin和Gd-IgA1水平。通过受试者工作特征曲线下面积（AUC）和综合辨别改善（IDI）分析评估了zonulin与Gd-IgA1的组合的诊断效率。
未经评估：与健康对照相比，我们发现IgAV-N和IgAN患者zonulin和Gd-IgA1水平均升高(P<.001).此外,与IgAN患者相比,IgAV-N患者的循环连蛋白水平甚至更高(P=0.020).在IgAN和IgAV-N的诊断中，在Gd-IgA1中添加zonulin比单独的Gd-IgA1显示出更好的预测性能，如显著增加的AUC(IgAN:0.805对0.708,P=.0021;IgAV-N:0.886对0.673,P<.001)和显著的IDI(IgAN:IDI0.136,P<.001;IgAV-N:IDI0.281,P<.001)所示。
未经证实：在IgAV-N患者和IgAN患者中均检测到循环连蛋白水平升高。循环zonulin和Gd-IgA1的联合检测被推荐作为IgAV-N和IgAN的非侵入性诊断生物标志物。
未经证实：总共73例IgAV-N患者，通过酶联免疫吸附试验评估了68例IgAN患者和54例健康对照的循环zonulin和Gd-IgA1水平。通过受试者工作特征曲线下面积（AUC）和综合辨别改善（IDI）分析评估了zonulin与Gd-IgA1的组合的诊断效率。
未经评估：与健康对照相比，我们发现IgAV-N和IgAN患者zonulin和Gd-IgA1水平均升高(P<.001).此外,与IgAN患者相比,IgAV-N患者的循环连蛋白水平甚至更高(P=0.020).在IgAN和IgAV-N的诊断中，在Gd-IgA1中添加zonulin比单独的Gd-IgA1显示出更好的预测性能，如显著增加的AUC(IgAN:0.805对0.708,P=.0021;IgAV-N:0.886对0.673,P<.001)和显著的IDI(IgAN:IDI0.136,P<.001;IgAV-N:IDI0.281,P<.001)所示。
未经证实：在IgAV-N患者和IgAN患者中均检测到循环连蛋白水平升高。循环zonulin和Gd-IgA1的联合检测被推荐作为IgAV-N和IgAN的非侵入性诊断生物标志物。
